Spontaneous resolution of hepatitis C virus (HCV) infection is a relatively infrequent event, and these individuals provide a unique opportunity to characterize correlates of protective immunity as an important first step in the development of vaccine candidates. The aim of this study was to directly and comprehensively enumerate HCV-nonstructural protein 3 (NS3) specific CD4 ؉ and CD8 ؉ T cells ex vivo from HLA diverse individuals who had been successful in spontaneously resolving HCV infection. We measured interferon gamma (IFN-␥) production with an ELISPOT assay using magnetic bead-separated CD4 ؉ or CD8 ؉ T cells in response to autologous DCs that had been pulsed with 15mer per peptides overlapping by 11 amino acids and spanning all of the NS3 protein (150 total peptides). All subjects with spontaneously recovered HCV infection demonstrated vigorous and multispecific CD4 ؉ T-cell responses to NS3 peptides, and 6 of 10 subjects demonstrated CD8 ؉ T-cell responses. More importantly, we identified novel, previously unpredicted antigenic regions, which in most cases elicited high frequencies within a given individual. In conclusion, subjects who have spontaneously eradicated HCV infection up to 35 years earlier demonstrate persistent CD4 ؉ and CD8 ؉ T-cell responses specific to NS3. By providing a comprehensive screening of all potential T-cell epitopes contained in the NS3 region, our strategy defines the breadth of the T-cell response and identifies novel, unpredicted specificities. (HEPATOLOGY 2003;37:577-589.) H epatitis C virus (HCV) is the major causative agent of chronic hepatitis and has an estimated global prevalence of 3%. 1 Several reports have indicated that viral clearance during acute HCV infection is associated with a multispecific CD4 ϩ T-cell response and that it must be maintained permanently to achieve long-term control of HCV. 2,3 Interestingly, although the vigor and breadth of the early cytotoxic T-lymphocyte (CTL) response are undisputedly crucial for recovery from acute infection, it has been suggested that ongoing exposure to HCV may be needed to maintain virus-specific memory CTL. 4, 5 This latter notion is based on studies that found extremely low frequencies of HCV-specific CD8 ϩ T cells in recovered patients with peptide-major histocompatibility complex (MHC) tetramer staining or with intracellular interferon gamma (IFN-␥) staining following stimulation with human leukocyte antigen A2 (HLA-A2)-restricted peptides. For example, one study 4 found that the frequency of circulating HCV-specific CD8 ϩ T cells in recovered subjects averaged less than .01%. However, studies that screen responses to single predicted epitopes are unlikely to provide an accurate representation of the total breadth of HCV-specific immune responses.
H epatitis C virus (HCV) is the major causative agent of chronic hepatitis and has an estimated global prevalence of 3%. 1 Several reports have indicated that viral clearance during acute HCV infection is associated with a multispecific CD4 ϩ T-cell response and that it must be maintained permanently to achieve long-term control of HCV. 2, 3 Interestingly, although the vigor and breadth of the early cytotoxic T-lymphocyte (CTL) response are undisputedly crucial for recovery from acute infection, it has been suggested that ongoing exposure to HCV may be needed to maintain virus-specific memory CTL. 4, 5 This latter notion is based on studies that found extremely low frequencies of HCV-specific CD8 ϩ T cells in recovered patients with peptide-major histocompatibility complex (MHC) tetramer staining or with intracellular interferon gamma (IFN-␥) staining following stimulation with human leukocyte antigen A2 (HLA-A2)-restricted peptides. For example, one study 4 found that the frequency of circulating HCV-specific CD8 ϩ T cells in recovered subjects averaged less than .01%. However, studies that screen responses to single predicted epitopes are unlikely to provide an accurate representation of the total breadth of HCV-specific immune responses.
To test our hypothesis that HCV-specific CD4 ϩ and CD8 ϩ responses against selected, previously identified epitopes are not representative of the total T-cell response, we have adopted the strategy of using overlapping pep-tides that span the HCV protein of interest to comprehensively examine the response to all potential epitopes. To date, we have focused on the nonstructural protein 3 (NS3) because in the majority of studies of self-limited infection, the CD4 ϩ T-cell response to NS3 has been the strongest and most consistently detected. 6, 7 Moreover, using a flow cytometric-based assay, we have recently reported an inverse correlation between NS3-specific CD4 ϩ T-cell responses and viral load. 8 Furthermore, NS3 is among the HCV antigens so far described as containing both CD4 ϩ -and CD8 ϩ -restricted epitopes. 9 The goals of our current study were to dissect the immunogenicity of the HCV NS3 protein with regard to the CD4 ϩ -and CD8 ϩ -mediated cellular immune responses directly ex vivo from an HLA-diverse group of subjects who had spontaneously resolved HCV infection. Because dendritic cells are highly efficient at displaying antigen (Ag) to T cells, we pulsed these professional antigen-presenting cells with 15mer peptides (overlapping by 11 amino acids) and screened for responses using an enzymelinked immunospot (ELISPOT) assay. We found vigorous CD4 ϩ T-cell responses in all individuals with resolved HCV infection and CD8 ϩ T-cell responses in 6 of the 10 individuals; the majority of the responses were not accounted for by previously recognized "immunodominant" determinants. Our findings underscore the limitations of screening for only known predicted epitopes and have potential implications for understanding the correlates of protective immunity.
Patients and Methods

Patients
The study protocol was approved by the human research committees and institutional review boards of Oregon Health and Science University and Portland VA Medical Center. The study comprised 10 subjects with risk factors for acquisition of HCV who demonstrated antibody reactivity to HCV ELISA 2.0 (Abbott Laboratories, Chicago, IL) and Chiron RIBA 3.0 but who lacked detectable HCV RNA by a qualitative polymerase chain reaction-based assay (with a lower limit of detection of 100 copies/mL) 10 and the Chiron Procleix Transcription Mediated Amplification (TMA) qualitative assay, which detects 50 HCV RNA copies/mL. 11 As controls, 7 HCVviremic, genotype 1a-infected patients (C1-C7), including 3 patients with mild histologic findings and 4 patients with at least moderate HAI and/or fibrosis subscores, 12 were studied (none were on antiviral treatment). Eight normal HCV-seronegative subjects without risk factors for acquisition of HCV were also studied. HLA class I typing was performed by a lymphocyte microcytotoxic method, and the class II typing was done by DNA polymerase chain reaction-SSP using established methods.
Synthetic Peptides for T-Cell Analysis
Overlapping peptides (n ϭ 150) were synthesized to span the complete amino acid sequence of the HCV NS3 protein derived from HCV-1 (genotype 1a, accession number M62321) and divided evenly into 3 peptide pools of 50. These pentadecamers (15mer peptides) overlapping by 11 amino acids were resuspended at 20 mg/mL with dimethyl sulfoxide (DMSO) then concentrated so that the final volume of DMSO in the assay would never exceed 1% in the pools of peptides. The concentration of DMSO for the individual peptides was .05%; the final concentration of peptides (either single or pooled) was 10 g/mL. Media with DMSO but without peptide or with irrelevant peptides (simian immunodeficiency virus, accession number M33262) was used as the negative control.
Cell Preparation
Peripheral Blood Mononuclear Cells. Peripheral blood mononuclear cells (PBMCs) from a unit blood draw or following leukophoresis were separated on FicollHistopaque density gradient (Amersham Pharmacia Biotech, Sweden) and then cryopreserved in media containing 80% fetal bovine serum (Hyclone), 10% DMSO, and 10% RPMI-1640 (Gibco) with penicillinstreptomycin as per manufacturer's recommendation.
Generation of Monocyte-Derived Dendritic Cells. Generation of monocyte-derived dendritic cells (DCs) was based on the method described by Romani et al. 13 Briefly, adherent cells were cultured in RPMI supplemented with 10% human serum, 4 mmol/L L-glutamine, 50 g/mL gentamicin, as well as granulocyte-macrophage colony-stimulating factor (GMCSF, 30 ng/mL, a kind gift of Immunex Inc., Seattle, WA) and interleukin 4 (IL-4) (10 ng/mL IL-4, R&D Systems) at day 0. Every other day, 10 ng/mL of GMCSF and 10 ng/mL of IL-4 were added to the culture, and, at day 5, cells were harvested with cell dissociation solution (Sigma C-5914). DCs used in ELISPOT assays (see below) were resuspended in RPMI plus 10% HS and plated at 10,000 cells/well in 96-well ELISPOT plates.
Antibodies. All antibodies were used for staining per manufacturers' recommendations. CD14-FITC, CD80-PE, CD83-PE, and HLA-DR-PerCP and isotype-FITC, isotype-PE, and isotype PerCP were obtained from BD Biosciences Pharmingen (San Diego, CA). CD80-PE, CD86-PE, HLA-class I-FITC, CD11c-PE, and isotype-FITC and isotype-PE were obtained from Caltag (Burlingame, CA).
Flow Cytometry. FACS analysis was performed at the Oregon Health Sciences University Flow Cytometry Core Facility using FACSCalibur flow cytometer and analyzed using Cell Quest software (Becton Dickinson, San Jose, CA).
MACS Bead Separation. Both CD4 ϩ and CD8 ϩ cells were positively separated from PBMCs using MACS superparamagnetic beads as per manufacturer's (Miltenyi, Auburn, CA) instructions. Separated cells were added in triplicate to DCs that been pulsed with peptide(s).
ELISPOT Assays
IFN-␥ production was detected using an established ELISPOT protocol. 8 Cells were incubated in plates for 40 hours before development of plates. Controls in the ELIS-POT assay were wells with purified T cells and DCs but no peptide or irrelevant SIV peptides (negative) or SEB (positive). Finally, spots were visualized by a peroxidase substrate kit (Vector SK-4200). After plates were dry, spots were quantified by a Zeiss microscope using KS ELISPOT software.
If a patient had a significant response to one of the pools of 50 peptides (effector frequency Ն1/50,000, as previously described 14 and a P value Ͻ .05 by multiple linear regression analysis), further ELISPOTs were performed using pools of 10 peptides, depending upon which pool of 50 peptides the person had responded to. Finally, single peptide analysis (in duplicate) was performed, depending on which pools of 10 peptides had elicited responses; in these experiments, 2.5 ϫ 10 5 beadpurified CD4 ϩ or CD8 ϩ cells were added to peptidepulsed DCs.
HLA Class I Peptide Tetramer Staining
HLA class I peptide tetramer specific for HLA A2 epitope NS3 1073-1081 was prepared at the NIAID tetramer facility. A total of 1 million PBMC were stained as previously described. 15 Flow cytometric analysis was performed with a fluorescence-activated cell sorter FACSCalibur (Becton Dickinson), and data analysis was performed using CELLQuest software (Becton Dickinson). Staining results were considered positive if the frequency of tetramer-positive cells was Ͼ0.04% of the total CD8 ϩ population (based on analysis of HCV-seronegative and HLA A2-negative controls).
Statistical Analyses
One-way analysis of variance and the Mantel-Haenszel 2 test were used for statistical comparison of means (Ϯ SEM) and proportions between groups, respectively. The JMP (SAS Institute Inc, Cary, NC) statistical package was used, and a P value of less than .05 was considered significant. For determination of effector cell frequencies of serial dilutions in triplicate, the general estimating equation in the GraphPad Prism 3.0 software package (San Diego, CA) was used. 
Results
The demographic and clinical data of HCV-seropositive subjects, including spontaneously recovered (R1-R10) and chronically viremic individuals (C1-C7), are summarized in Table 1 .
Use of Dendritic Cells as Ag-Presenting Cells
DCs are the most potent antigen presenting cells (APCs) described to date, with specialized functions, including the ability to take up, process, and present Ag and activate both CD4 ϩ helper and CD8 ϩ cytotoxic T cells. 16, 17 DCs constitutively express surface MHC peptide molecules (10-100 times higher than on other APCs such as B cells and monocytes), and, following Ag uptake, up-regulate expression of molecules central in T-cell adhesion and signaling. For the purposes of optimizing detection of specific T cells, we derived autologous DCs as previously described. 13, 19 Numerous laboratories [20] [21] [22] and our experience indicate that DCs are significantly more potent APCs in vitro, increasing the sensitivity for detection of responses, as compared with typical APCs residing within the PBMC population ( Fig. 1 ). Because DCs are relatively immature at the start of the coculture phase, they are highly efficient in taking up and processing peptides; after incubation with T lymphocytes for an additional 24 hours, they become mature, as manifested by up-regulation of key costimulatory molecules (Fig. 2) . Additionally, an advantage for using DCs as compared with transformed lymphoid cell lines as APCs is that the latter frequently yield high background (because of endogenous Epstein-Barr virus responses), and, similarly, subjects with prior small pox vaccination routinely have high background responses to vaccinia.
Interestingly, the median yield of DCs (defined as the percentage of the obtained DC numbers to the starting PBMC numbers) differed among the 3 groups of subjects: 7.5%, 3.5%, and 13.2% for recovered, chronically HCV infected, and normal controls, respectively (P ϭ .001, Wilcoxon rank sums). However, there was no significant difference in the expression of HLA class I, class II, and costimulatory markers CD80 (B7.1) or CD86 (B7.2) according to the patient subset studied ( Table 2) .
Quantitation of Total HCV NS3-Specific CD4 ؉ and CD8 ؉ T-Cell Responses Using Overlapping Peptide Pools in an ELISPOT Assay
The strategy we have adopted to assess the entire repertoire of NS3-specific T-cell responses is to synthesize 15 amino acids in length, overlapping by 11 amino acids that have been shown to stimulate either CD4 ϩ or CD8 ϩ T cells, depending on the purified population added to the ELISPOT assay. The size of these peptides allows them to be processed and presented by HLA class I molecules (which typically bind peptides 8 to 11 amino acids long) and by HLA class II molecules (whose binding groove accommodates peptides ranging from about 10 to 25 amino acids long). In theory, because the overlapping 15mer peptides contain every possible T-cell epitope, they can be used to quantify total T-cell responses independently of the patient's MHC haplotype, as shown recently for Mycobacterium tuberculosis, 23 cytomegalovirus, 24 and HIV infection. 25 The complete amino acid sequence of the HCV NS3 protein derived from HCV-1 (genotype 1a) was covered by 150 overlapping peptides, divided evenly into 3 peptide pools of 50: pool NS3-A, amino acids (aa) 1007-1218; NS3B, aa 1207-1418; and NS3C, aa 1407-1618.
To determine the spectrum of HCV NS3 peptides recognized by subjects with resolved infection, we tested DCs were grown as described in the Patients and Methods section; for comparison, following CD4 and CD8 depletion, 10,000 residual cells ("other APCs") were pulsed for the same duration (4 hours) with the same peptides at 10, 25, or 50 g/mL (final concentration in well), and 2.5 ϫ 10 5 T cells were added per well. The "other APCs" included B cells (CD19 ϩ , 27%), NK cells (CD56-positive, 13%), monocytes (CD14 ϩ , 25%), and double-negative CD3 ϩ T cells (5% CD4 Ϫ CD8 Ϫ ). *P Ͻ .05; **P Ͻ .01.
IFN-␥ ELISPOT responses elicited by purified CD4 ϩ and CD8 ϩ T cells. These cells required neither antigen restimulation nor IL-2 addition in vitro, suggesting they were memory cells with effector function. Remarkably, as shown in Fig. 3 , all the recovered subjects demonstrated significant CD4 ϩ T-cell responses to all 3 of the NS3 pools, although the relative effector cell frequencies varied among the individuals. The responses to the NS3-A 1007-1218 pool ranged from 1/4,300 (R2) to 1/41,100 (R9); the responses to the NS3-B 1207-1418 pool ranged from 1/3,700 (R10) to 1/28,700 (R9); the responses to the NS3-C 1407-1618 pool ranged from 1/2,005 (R10) to 1/28,640 (R8). Strengthening the argument that these responses reflected a recall response specific to HCV was the fact that they were absent in the normal subjects tested. Moreover, these peptide pools did not elicit IFN-␥ production from any of the chronically viremic patients (Fig. 3) .
Although NS3-specific CD8 ϩ T-cell responses to the peptide pools were considerably less frequent, in 6 of the 10 recovered subjects, we were able to detect significant responses to at least one of the pools. Only 2 subjects (R2 and R3) had a significant CD8 ϩ response to all 3 of the pools: R1 responded to 2 of the pools, and R5, R9, and R10 responded only to pool NS3-A. Pool NS3-A 1007-1218 elicited the most frequent class I-restricted response, with 6 of 10 subjects exhibiting CD8 ϩ T-cell responses (effector frequency range: 1/1,254 in R1 to 1/41,990 in R3). Again, none of the 8 normal control subjects demonstrated detectable responses to any of these NS3 pools, suggesting that responses in subjects with resolved infection did not represent cross-reactive responses to an unrelated antigen. 26 None of the chronically infected individuals (C1-C7) demonstrated CD8 ϩ T-cell responses (Fig. 3) . To determine whether the lack of responses in chronically HCV-infected patients could be related to functional impairment of DCs, 27, 28 we tested responses to 2 other viral antigens (influenza and EpsteinBarr virus). In accord with previous reports, 27 DCs derived from HCV-infected individuals were functionally competent and, in fact, superior to nonprofessional APCs in eliciting T-cell responses (Fig. 4) . Fig. 3 . HCV NS3-specific CD4 ϩ and CD8 ϩ T-cell responses in peripheral blood of 10 recovered subjects (HCV antibody positive, RNA negative), panel 3A, and representative chronically infected (C1-C3), next page panel 3B, and normal subjects (N1-N3), next page panel 3C. After pulsing autologous DCs with overlapping peptides, divided evenly into 3 peptide pools of 50 (pool NS3-A 1007-1218 , NS3B 1207-1418 , and NS3C 1407-1618 ), highly purified CD4 ϩ and CD8 ϩ T cells were added in triplicate in serial dilution (5 ϫ 10 5 , 2.5 ϫ 10 5 , 1.25 ϫ 10 5 , and 0.6 ϫ 10 5 cells). IFN-␥ spot formation was assessed after 40 hours of incubation and quantified by a Zeiss microscope using KS ELISPOT software. Control wells without peptide or with irrelevant peptide were used in each experiment. Effector cell frequencies were determined by linear regression analysis after subtracting controls. *P Ͻ .05; **P Ͻ .005; ***P Ͻ .0001.
Identification of Single HCV Peptide Responses
To identify the breadth and vigor of specific peptide responses, each pool of 50 peptides that had elicited significant T-cell responses in a given individual was broken down into 5 corresponding mixtures of 10 peptides and then screened as described in the Patients and Methods section. A representative example of this strategy is shown in Fig. 5 . This approach appeared conservative because we occasionally failed to find significant individual peptide responses despite responses to their corresponding pools of 10 peptides. Moreover, because of the theoretical concern of in vitro peptide competition, i.e., large pools of peptides underestimating the actual frequency of the sum of individual peptides, in selected subjects, we tested individual peptides when the larger peptide pools had failed to elicit significant responses. T cells that were unresponsive to the pools failed to respond to any of the individual peptides composing that particular pool. Figure 6 demonstrates the specificities and frequencies of CD4 ϩ T cells directed against the individual NS3 peptides in the resolved subjects (R1-R10). Table 3 shows the highly antigenic regions (i.e., effector cell frequencies greater than 1/5,000) in the 7 subjects who demonstrated this level of reactivity to any of the NS3 peptides. Four of the 7 subjects responded with high frequencies of CD4 ϩ T cells specific to NSB 1303-1330 region, including subjects R1, R3, R6, and R10. Four of the 7 subjects (R1, R2, R4, and R5) demonstrated high frequencies of CD4 ϩ T cells to NS3B 1387-1402 region. It has been suggested previously 6 that epitope 1388-1407 was recognized by patients carrying HLA-DRB1*15, and all 4 of these subjects shared this allele in common. Figure 7 shows the 6 resolved subjects who demonstrated NS3-specific class I-restricted responses. CD8 ϩ T-cell responses are in general more oligospecific, i.e., targeted to a smaller number of epitopes, than observed for CD4 ϩ T Fig. 4 . CD8 ϩ T-cell responses to immunodominant Epstein-Barr virus (GLCTLVAML) and influenza (GILGFVFTL) epitopes in a chronically infected patient (C1). In triplicate, 5.0 ϫ 10 5 CD8 ϩ T cells cocultured with DCs and the HLA-A2-restricted peptides elicited greater responses than PBMC that had been depleted of CD4 ϩ cells ("CD8 ϩ others"; P Ͻ .03). Fig. 3 , the pools of 50 peptides identified significant CD4 ϩ T-cell responses following stimulation with pools A, B, and C and significant CD8 ϩ T-cell responses following stimulation with pools A and B but not pool C. Five mixes of 10 peptides were then tested for each larger pool that had elicited a response. For the purposes of illustration in this experiment, all individual peptides were tested (in duplicate), although, typically, individual peptides would be tested only if responses to the peptide mixes of 10 were at least twice (and greater than 5 ELISPOTs) above background. The levels of responsiveness to the larger pools of peptides were reflected in the responsiveness to the constituent pools of 10 peptides and to the individual peptides. As shown, no significant response to a candidate peptide would have been missed if screening had been limited to only those peptide mixes demonstrating responses. cells in the same subject(s). Table 4 shows the peptide regions eliciting IFN-␥-producing frequencies of 1/5,000 or greater. Among the NS3 peptides, NS3A 1067-1082 (QTFLATCINGVCWTV) and NS3A 1071-1086 (ATC-INGVCWTVYHGA) are the most frequently identified. Notably, these peptides share 11 amino acids, suggesting that, in the donors reactive to both peptides (R1, R2, R5), this overlap may define the epitope. This overlap contains NS3 1073-1081 , which has previously been shown to represent an immunodominant HLA-A2-restricted CTL target in chronically infected patients, 15 and peptide-MHC tetramer analysis confirmed specific responses to this epitope (Fig. 8) .
CD4 ؉ T-Cell Responses
CD8 ؉ T-Cell Responses
We synthesized and tested this NS3 1073-1081 peptide as well as 3 other HLA-A2 restricted, NS3-derived peptides in 7 resolved, 2 chronically infected, and 1 normal subject, all of whom were HLA A2-positive. Table 5 shows the CD8 ϩ effector T-cell frequencies following stimulation with these peptides. The correlation between effector frequencies enumerated using these optimized 9mer or 10mer and our 15mer peptides was highly significant (r ϭ .69, P Ͻ .0001). To quantitate the total CD8 ϩ T-cell responses obtained with overlapping peptides, the IFN-␥ ELISPOTs cannot simply be added because complete or partial epitopes may be contained in the overlaps. In an attempt to estimate what proportion of responses would have been accounted for if we had screened only with the 4 HLA-A2-restricted peptides, we divided the total number of spots induced following stimulation with these optimized 9mer or 10mer peptides by the sum of the peak number of spots for the individual peptide(s) shown in Fig. 7 . This percentage is shown in Table 5 and ranged from 2.7% to 100%. Importantly, the peptide eliciting the single most dominant response in subjects R1, R2, and R3 did not span any of the known HLA-A2-restricted epitopes and therefore would have been missed by limiting our analysis to these previously published peptide regions.
Discussion
Recent advances in the ability to precisely quantify antigen-specific T cells have enhanced our understanding of potential roles for these cells in the clearance or persistence of HCV infection. In this report, we utilized a DCbased IFN-␥ ELISPOT assay to characterize the breadth and specificity of CD4 ϩ and CD8 ϩ T cells in subjects who had spontaneously cleared HCV infection in the remote past. We demonstrate that all recovered subjects have vigorous and multispecific CD4 ϩ T-cell responses to NS3 peptides and, in 6 of the 10 subjects, CD8 ϩ T-cell responses, suggesting that the NS3 Ag may be an important candidate for inclusion in a vaccine designed to elicit both CD4 ϩ and CD8 ϩ T-cell immunity.
Existing data demonstrate that a strong and persistent CD4 ϩ T-cell response to NS3 is critical for resolution of acute HCV infection. Diepolder et al. 6 from Munich found that, in 4 patients with spontaneous viral clearance, the immune response was dominated by a single, promiscuous 14-aa epitope (aa 1248-1261) presented to CD4 ϩ T cells by HLA-DR4, -DR11, -DR12, -DR13, and -DR16. Although 5 resolved subjects (R3, R6, R7, R8, R9) in the current analysis expressed these alleles, only subject R3 demonstrated high effector frequency (1/2,762) to the peptide containing this epitope (peptide 61). Subjects R1 and R7 demonstrated lower level responses to this peptide. Moreover, in none of our subjects did this peptide elicit the single most dominant response. These results, therefore, indicate that limiting our screening to previously identified regions would not provide a complete assessment of the CD4 ϩ T-cell repertoire. It is possible that these disparate findings with regard to the relative "immunodominance" of this peptide are related to different Table 3 ).
methodologies to generate estimates in these studies, i.e., T-cell cloning versus direct ex vivo analysis of cytokine production. It is now recognized that the former approach may introduce an in vitro bias in relation to effector functions; furthermore, it has been suggested that highly activated cells may undergo apoptosis during the multiple rounds of stimulation and thus may not be detected in the final analysis. 29 There is considerable debate regarding the role of HCV-specific CTL responses in viral clearance. Whereas the frequencies of CTL responses among spontaneously resolved infection have been low or undetectable in a number of studies, 4,5 Takaki et al. 30 found that 10 of 11 women who had recovered after receiving HCV-infected immunoglobulin 18 to 20 years earlier mounted recall IFN-␥ ELISPOT responses to at least one HLA-A2-restricted peptide, whereas none of the chronically infected patients did so. In our current study, 6 of the HLA-A2 positive recovered individuals demonstrated responses to NS3 1073-1081 (range 1/1,531 to 1/22,667), and 4 subjects demonstrated responses to peptide NS3 [1406] [1407] [1408] [1409] [1410] [1411] [1412] [1413] [1414] [1415] . More importantly, in 3 of these subjects, novel antigenic regions would not have been identified by less comprehensive screening of peptide responses. These results are in accord with a recent analysis by Lauer et al. 31 that screened the breadth and specificity of CD8 T-cell responses using 20mer peptides. In our ELISPOT assays, the use of dendritic cells, the most efficient type of cells involved in antigen presentation, perhaps allowed a more efficient activation of CTLs, particularly of those subdominant T-cell specificities that require higher levels of activation (Fig. 1) . We have demonstrated that DCs are functionally superior to nonprofessional APCs (residing in the normal PBMC population) in eliciting HCV-, Epstein-Barr virus-, and influenza-specific responses. We chose to quantitate viral-specific effector cell frequencies using the ELISPOT assay based on recent reports indicating that it is several-fold more sensitive and quantitative when compared with other more conventional assays, including proliferation, chromium release, and limiting dilution assays. 32 We recognize that exclusive reliance on techniques that detect gamma interferon may theoretically underestimate effector cell frequencies, particularly if CD8 ϩ T cells are deficient in IFN-␥ expression. 33, 34 However, in recent studies, results from cytotoxicity assays and direct quantitation by tetramers have mirrored IFN-␥ production. 31, 32, 35 Emerging data suggest that CTLs that secrete IFN-␥ have direct effects on virus replication in infected cells and may be more important in vivo for protection against viral infections than perforin-or fas-mediated lysis. 36, 37 The proportion and pace of spontaneous resolution following acute HCV has recently been called into question, 38, 39 and it remains unknown at the present time whether certain NS3-specific CTLs emerge during viremia (and do not represent "protective" epitopes), whereas the emergence of specific CTLs precede or coincide with viral clearance. Clearly, responses against multiple epitopes reduce the likelihood of escape and persistence through antigenic variation, 40 but it is unknown whether all these responses are sustained indefinitely.
Several additional aspects of our study merit further discussion. We synthesized HCV 1a-derived peptides to screen responses in part because of the exponential increase in the prevalence of this genotype and its association with injection drug use, 41, 42 which was the predominant risk factor among our subjects. Recent data suggest that injection drug users who clear HCV infection once are more likely to clear it again, 43 and it is possible that our subjects had been exposed to multiple HCV strains. Because our subjects had their primary exposure 8 to 35 years earlier, it was not possible to know whether the initial infecting viral strain(s) coded for sequences that differed from our peptides. Viral heterogeneity may have contributed to the different levels of immune responses detected (or not detected) with our assays. In this regard, Fig. 7 . Mapping of specificity and frequency of CD8 ϩ T cells following stimulation with NS3 specific peptides in duplicate (from pools A, B, and C). ELISPOTs shown are per 250,000 highly purified CD8 ϩ T cells. Numbered peptides correspond to those eliciting responses Ͼ1/ 5,000 (see Table 4 ). [1491] [1492] [1493] [1494] [1495] [1496] [1497] [1498] [1499] [1500] [1501] [1502] [1503] [1504] [1505] [1506] [1507] [1508] [1509] [1510] . It is possible that viral heterogeneity (and therefore differences in initial cognate antigen) may have contributed to the variability in vigor of responses in these HLA class II identical individuals. Interestingly, the amino acid conservation of the 3 peptides eliciting highly frequent responses in these 2 subjects averages 93% (range 80% to 100%), whereas the amino acid conservation of NS3C 1491-1510 is 82% (range 65% to 100%) across 32 genotype sequences. 44 In summary, we have developed a sensitive and unbiased strategy to identify CD4 ϩ and CD8 ϩ T-cell responses to HCV peptides directly ex vivo. Multispecific helper and cytotoxic T-cell responses persist for decades after spontaneous resolution, and the repertoire of these responses is more diverse than originally anticipated. Our strategy may be a promising approach to screening HCV genome-wide responses, and we believe these data will have important implications for identifying potential vaccine candidates. 
